DuPont agrees to sell Aramids business to Arclin for $1.8 billion valuation
DuPont signed a Transaction Agreement on August 29, 2025 to sell its Aramids business, which makes Kevlar and Nomex, to Arclin at a valuation of approximately $1.8 billion. The deal is subject to customary closing conditions, including regulatory approvals, and the sale is expected to bring pre-tax cash proceeds of about $1.2 billion plus a $300 million note receivable and a minority equity stake.
Key points
- Valuation of the Aramids business is approximately $1.8 billion, with about $1.2 billion in pre-tax cash proceeds at closing
- DuPont will also receive a $300 million note receivable and a non-controlling common equity interest currently valued at $325 million, about a 17.5% stake
- Either party can terminate if the deal does not close by May 1, 2026, with two two-month extensions available in certain cases
- Closing requires regulatory approvals, including under Hart-Scott-Rodino and in the European Union, Japan, China, South Korea and the United Kingdom
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 02, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.